Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00309985 · ClinicalTrials.gov registry record · Phase 3
Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer
A Phase 3 study, sponsored by ECOG-ACRIN Cancer Research Group.
- Completed
- Registry status
- Phase 3
- Development phase
- 790
- Enrollment target
NCT00309985 is a Phase 3 study that has completed, run by ECOG-ACRIN Cancer Research Group. The registered enrollment target is 790 participants.
The verdict
NCT00309985, a Phase 3 study, has completed, sponsored by ECOG-ACRIN Cancer Research Group.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 790 participants
- Enrollment target
Study Summary
RATIONALE: Androgens can cause the growth of prostate cancer cells. Androgen ablation therapy may stop the adrenal glands from making androgens. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known whether androgen-ablation therapy is more effective with or without docetaxel in treating metastatic prostate cancer. PURPOSE: This randomized phase III trial is studying androgen-ablation therapy and chemotherapy to see how well they work compared to androgen-ablation therapy alone in treating patients with metastatic prostate cancer.
Interventions
- DRUG docetaxel
- DRUG androgen-deprivation therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 790 participants |
| Start Date | 2006-09-26 |
| Est. Completion | 2025-01-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00309985
The ClinicalTrials.gov registry entry for NCT00309985 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 790 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ECOG-ACRIN Cancer Research Group, which has 75 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which docetaxel is the first listed.
NCT00309985 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00309985 about?
NCT00309985 is a clinical study titled "Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer". RATIONALE: Androgens can cause the growth of prostate cancer cells. Androgen ablation therapy may stop the adrenal glands from making androgens. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them fr...
What is the current status of trial NCT00309985?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 790 participants. The study started on 2006-09-26. Estimated completion is 2025-01-31.
What interventions are being tested in trial NCT00309985?
The interventions under investigation include: docetaxel (DRUG), androgen-deprivation therapy (DRUG).
Who is sponsoring clinical trial NCT00309985?
This trial is sponsored by ECOG-ACRIN Cancer Research Group, which has 75 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.